KAWASAKI INSTITUTE OF INDUSTRIAL PROMOTION (Japon)
NANOCARRIER CO., LTD. (Japon)
EDUCATIONAL FOUNDATION KYORIN GAKUEN (Japon)
KYOTO PREFECTURAL PUBLIC UNIVERSITY CORPORATION (Japon)
Inventeur(s)
Kataoka Kazunori
Uchida Satoshi
Abbasi Saed Amjad Yousef
Masai Miki
Hayashi Akimasa
Abrégé
The present invention provides a composition for transdermal administration, which contains a nucleic acid. More specifically, the present invention provides a composition for transdermal administration, the composition containing a nucleic acid, in which the nucleic acid comprises RNA. The composition is administered by an administration method comprising spraying the composition onto the surface of a target tissue, in which the spraying of the composition is performed by applying a pressure to the composition so that the composition is sprayed toward the target tissue and penetrates through the surface of the target tissue.
A61K 31/7105 - Acides ribonucléiques naturels, c.-à-d. contenant uniquement des riboses liés à l'adénine, la guanine, la cytosine ou l'uracile et ayant des liaisons 3'-5' phosphodiester
A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
A61K 39/39 - Préparations médicinales contenant des antigènes ou des anticorps caractérisées par les additifs immunostimulants, p. ex. par les adjuvants chimiques
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
A61M 5/307 - Seringues pour injection par projection, sans aiguille, p. ex. utilisables avec des ampoules ou des cartouches échangeables les agents étant expulsés de l'injecteur par un fluide sous pression
C12N 15/88 - Introduction de matériel génétique étranger utilisant des procédés non prévus ailleurs, p. ex. co-transformation utilisant la micro-encapsulation, p. ex. utilisant des vésicules liposomiques
2.
NUCLEIC ACID FOR SUPPRESSING GENE EXPRESSION OF DISEASE-SPECIFIC COL3A1 MUTANT ALLELE AND PHARMACEUTICAL COMPOSITION FOR TREATING VASCULAR EHLERS-DANLOS SYNDROME
The present invention provides a pharmaceutical composition for use in treatment of a disease caused by a mutation in collagen 3A1. This pharmaceutical composition is for treating a disease caused by a collagen 3A1 mutant in a subject having a gene encoding the mutant and a gene encoding the wild type, said pharmaceutical composition containing a nucleic acid selected from siRNAs and shRNAs. The mutant is a gene encoding collagen 3A1 in which the base G at position 755 in the base sequence represented by SEQ ID No:27 is substituted with T or a gene encoding collagen 3A1 in which the base G at position 547 in the base sequence represented by SEQ ID No:27 is substituted with A. The nucleic acid suppresses the expression of the mutant more strongly than the expression of the wild type.
A61K 31/7088 - Composés ayant au moins trois nucléosides ou nucléotides
A61K 31/713 - Acides nucléiques ou oligonucléotides à structure en double-hélice
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
A61P 9/00 - Médicaments pour le traitement des troubles du système cardiovasculaire
C07K 14/78 - Peptides du tissu connectif, p. ex. collagène, élastine, laminine, fibronectine, vitronectine ou globuline insoluble à froid [CIG]
C12N 5/10 - Cellules modifiées par l'introduction de matériel génétique étranger, p. ex. cellules transformées par des virus
C12N 15/113 - Acides nucléiques non codants modulant l'expression des gènes, p. ex. oligonucléotides anti-sens
C12N 15/12 - Gènes codant pour des protéines animales
3.
POLYMER MICELLE CARRIER COMPOSITION AND MEDICINE-CONTAINING POLYMER MICELLE COMPOSITION
Provided are a polymer micelle carrier composition and a medicine-containing polymer micelle composition that enable improvement of efficiency of penetration of a medicine to the skin. This polymer micelle carrier composition includes: an aqueous medium; and a block copolymer that forms a polymer micelle structure in the aqueous medium and that has a hydrophilic polymer chain segment and a hydrophobic polymer chain segment. The polymer micelle carrier composition further contains a penetration accelerator at concentration a such that the contact angle ratio calculated according to formula A is less than or equal to 0.82.
A61K 47/10 - AlcoolsPhénolsLeurs sels, p. ex. glycérolPolyéthylène glycols [PEG]PoloxamèresAlkyléthers de PEG/POE
A61K 47/34 - Composés macromoléculaires obtenus par des réactions autres que celles faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. polyesters, acides polyaminés, polysiloxanes, polyphosphazines, copolymères de polyalkylène glycol ou de poloxamères
A61K 47/44 - Huiles, graisses ou cires couvertes par plus d’un des groupes Huiles, graisses ou cires naturelles ou naturelles modifiées, p. ex. huile de ricin, huile de ricin polyéthoxylée, cire de lignite, lignite, gomme-laque, colophane, cire d’abeille ou lanoline
4.
DRUG-CONJUGATED BLOCK COPOLYMER, BLOCK COPOLYMER, AND METHOD FOR PRODUCING DRUG-CONJUGATED BLOCK COPOLYMER
The present invention provides a polymer DDS which enables the controlled release of a drug having a carboxyl group. A drug-conjugated block copolymer according to the present invention is represented by the general formula: A-B. In the general formula, A represents a polyethylene glycol chain segment; and B represents a copolyamino acid chain segment containing a repeating unit represented by general formula (i) and/or (ii), wherein X in each of formulae (i) and (ii) represents a residue of the drug and the residue may have a linking group.
A61K 47/60 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique macromoléculaire, p. ex. une molécule oligomérique, polymérique ou dendrimérique obtenu par des réactions autres que celles faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. polyurées ou polyuréthanes le composé organique macromoléculaire étant un oligomère, un polymère ou un dendrimère de polyoxyalkylène, p. ex. PEG, PPG, PEO ou polyglycérol
A61K 31/445 - Pipéridines non condensées, p. ex. pipérocaïne
A61K 47/34 - Composés macromoléculaires obtenus par des réactions autres que celles faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. polyesters, acides polyaminés, polysiloxanes, polyphosphazines, copolymères de polyalkylène glycol ou de poloxamères
C08G 69/40 - Polyamides contenant de l'oxygène sous forme de groupes éther
C08G 81/00 - Composés macromoléculaires obtenus par l'interréaction de polymères en l'absence de monomères, p. ex. polymères séquencés
Provided is a pharmaceutical polymer micelle composition showing a significantly enhanced effect compared with a drug (E7974) that is a hemiasterlin derivative. The pharmaceutical polymer micelle composition provided by the present invention carries E7974 represented by formula (i) and an antibody having a CDR sequence being the same as the CDR sequence of trastuzumab or cetuximab or a fragment of the antibody, each bonded thereto by a chemical bond. In this composition, E7974 is bonded to a side chain of a reducing aspartic acid group of a block copolymer constituting the polymer micelle, while the antibody or a fragment thereof is bonded to the free end side of a polyethylene glycol chain segment of another block copolymer.
A61K 38/00 - Préparations médicinales contenant des peptides
A61K 47/34 - Composés macromoléculaires obtenus par des réactions autres que celles faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. polyesters, acides polyaminés, polysiloxanes, polyphosphazines, copolymères de polyalkylène glycol ou de poloxamères
A61K 47/42 - ProtéinesPolypeptidesLeurs produits de dégradationLeurs dérivés p. ex. albumine, gélatine ou zéine
A61K 47/60 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique macromoléculaire, p. ex. une molécule oligomérique, polymérique ou dendrimérique obtenu par des réactions autres que celles faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. polyurées ou polyuréthanes le composé organique macromoléculaire étant un oligomère, un polymère ou un dendrimère de polyoxyalkylène, p. ex. PEG, PPG, PEO ou polyglycérol
03 - Produits cosmétiques et préparations de toilette; préparations pour blanchir, nettoyer, polir et abraser.
Produits et services
Skin lotions; milky lotions; beauty serums; cosmetic creams;
cosmetics for basic skin care; medicated cosmetics;
moisturizing cosmetics for skin; cosmetics for massage; hair
rinses; hair treatments; cosmetics for hair care; bath
salts, other than for medical purposes; bath additives,
other than for medical purposes; hair tonics for scalp and
hair care [cosmetics]; deodorants for human body; cosmetics;
facial wash; body soaps; shampoos; soaps; breath fresheners;
deodorants for pets; perfume and ethereal oils; extracts of
flowers [perfumes]; dentifrices; anti-static preparations
for household purposes; de-greasing preparations for
household purposes; rust removing preparations; fabric
softeners for laundry use; laundry bleach; laundry starch;
seaweed gelatine for laundry use [funori ].
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Pharmaceutical preparations; pharmaceutical preparations and
substances for the treatment of cancer; pharmaceutical
preparations and substances for the prevention of cancer.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Pharmaceutical preparations; pharmaceutical preparations and
substances for the treatment of cancer; pharmaceutical
preparations and substances for the prevention of cancer.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Pharmaceutical preparations; pharmaceutical preparations and
substances for the treatment of cancer; pharmaceutical
preparations and substances for the prevention of cancer.
01 - Produits chimiques destinés à l'industrie, aux sciences ainsi qu'à l'agriculture
03 - Produits cosmétiques et préparations de toilette; préparations pour blanchir, nettoyer, polir et abraser.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
42 - Services scientifiques, technologiques et industriels, recherche et conception
Produits et services
Reagents for chemical research use [chemicals]; chemical
reagents for gene research use [other than for medical and
veterinary use]: chemical reagents for laboratory use which
are used for introducing biological active substance such as
molecules and molecular assemblies of peptide and nucleic
acids into cells such as prokaryotic cells and eukaryotic
cells [other than for medical and veterinary use]; chemical
reagents [other than for medical and veterinary use];
polyethylene glycol-polyamino acid block copolymer
[chemicals]; polymers [chemicals]: chemicals for laboratory
use [other than for medical and veterinary use]; chemical
preparations for use in the manufacture of complexes which
combine with nucleic acid materials for introducing the
nucleic acid materials into cells; chemical preparations for
use in the manufacture of polymeric micelle preparations;
chemical preparations for use in the manufacture of
medicines; chemicals for use in the manufacture of
medicines; humectants; chemical preparations for use in the
manufacture of cosmetics; chemicals for use in the
manufacture of cosmetics; chemical preparations for use in
the manufacture of dietary supplements; chemicals for use in
the manufacture of foods; chemical additives for use in
manufacture; surface-active chemical agents; chemical
agents; chemicals for industrial purposes; chemicals for
used in science [other than for medical and veterinary use];
reagents for medical and pharmaceutical research use. Skin lotions; milky lotions; beauty serums; cosmetic creams;
cosmetics for basic skin care; moisturizing cosmetics for
skin; cosmetics for massage; hair rinses; hair treatments;
cosmetics for hair care; bath salts, other than for medical
purposes; bath additives, other than for medical purposes;
hair tonics for scalp and hair care (cosmetics); deodorants
for human body; cosmetics; facial wash; body soaps;
shampoos; soaps; breath fresheners; deodorants for pets;
perfume and ethereal oils; extracts of flowers [perfumes];
dentifrices; anti-static preparations for household
purposes; de-greasing preparations for household purposes;
rust removing preparations; fabric softeners for laundry
use; laundry bleach; laundry starch; seaweed gelatine for
laundry use [Funori]. Chemical reagents for medical purposes; anticancer drugs;
anticancer preparations; pharmaceutical preparations and
compositions for the treatment and prevention of cancer;
polymeric micelle anticancer drugs; polymeric micelle
anticancer preparation; polymeric micelle pharmaceutical
preparations and compositions for the treatment and
prevention of cancer; polymeric micelle pharmaceutical
preparations; anticancer drugs using polymers; anticancer
preparations using polymers; pharmaceutical preparations and
compositions using polymers for the treatment and prevention
of cancer; hair growth tonic; medicinal hair growth
preparations; medicated creams for treating dermatological
conditions; medicated lotions for treating dermatological
conditions; detergents for medical purposes; pharmaceutical
preparations using polymers; deodorizers for household
purposes; pharmaceutical preparations; medicines for human
purposes; dietary supplements for humans; dietetic beverages
adapted for medical purposes; dietetic foods adapted for
medical purposes; lacteal flour for babies; beverages for
babies; food for babies; dietary supplements for animals;
dental materials; deodorizers for industrial purposes;
medicated cosmetics. Research and developments of anticancer drugs and anticancer
preparations; research and developments in the field of
pharmaceutical technologies concerning polymeric micelle;
research, testing and analysis services for development of
products using polymeric micelle; testing, inspection or
research of pharmaceuticals, cosmetics and foodstuffs;
development of pharmaceutical products, cosmetic products
and foodstuffs; consultancy relating to development of
pharmaceutical products, cosmetic products and foodstuffs;
providing information related to development of
pharmaceutical products, cosmetic products and foodstuffs;
research and development in the pharmaceutical fields and
chemical fields; testing of products, product development,
product research; consultancy in the field of product
development; analysis and evaluation of product development.
01 - Produits chimiques destinés à l'industrie, aux sciences ainsi qu'à l'agriculture
05 - Produits pharmaceutiques, vétérinaires et hygièniques
42 - Services scientifiques, technologiques et industriels, recherche et conception
Produits et services
Reagents for chemical research use [chemicals]; chemical
reagents for gene research use [other than for medical and
veterinary use]; chemical reagents for laboratory use which
are used for introducing biological active substance such as
molecules and molecular assemblies of peptide and nucleic
acids into cells such as prokaryotic cells and eukaryotic
cells [other than for medical and veterinary use]; chemical
reagents [other than for medical and veterinary use];
polyethylene glycol-polyamino acid block copolymer
[chemicals]; polymers [chemicals]; chemicals for laboratory
use [other than for medical and veterinary use]; chemical
preparations for use in the manufacture of complexes which
combine with nucleic acid materials for introducing the
nucleic acid materials into cells; chemical preparations for
use in the manufacture of polymeric micelle preparations;
chemical preparations for use in the manufacture of
medicines; chemicals for use in the manufacture of
medicines; humectants; chemical preparations for use in the
manufacture of cosmetics; chemicals for use in the
manufacture of cosmetics; chemical preparations for use in
the manufacture of dietary supplements; chemicals for use in
the manufacture of foods; chemical additives for use in
manufacture; surface-active chemical agents; chemical
agents; chemicals for industrial purposes; chemicals for
used in science [other than for medical and veterinary use];
reagents for medical and pharmaceutical research use. Chemical reagents for medical purposes; anticancer drugs;
anticancer preparations; pharmaceutical preparations and
compositions for the treatment and prevention of cancer;
polymeric micelle anticancer drugs; polymeric micelle
anticancer preparation; polymeric micelle pharmaceutical
preparations and compositions for the treatment and
prevention of cancer; polymeric micelle pharmaceutical
preparations; anticancer drugs using polymers; anticancer
preparations using polymers; pharmaceutical preparations and
compositions using polymers for the treatment and prevention
of cancer; hair growth tonic; medicinal hair growth
preparations; medicated creams for treating dermatological
conditions; medicated lotions for treating dermatological
conditions; detergents for medical purposes; pharmaceutical
preparations using polymers; deodorizers for household
purposes; pharmaceutical preparations; medicines for human
purposes; dietary supplements for humans; dietetic beverages
adapted for medical purposes; dietetic foods adapted for
medical purposes; lacteal flour for babies; beverages for
babies; food for babies; dietary supplements for animals;
dental materials; deodorizers for industrial purposes. Research and developments of anticancer drugs and anticancer
preparations; research and developments in the field of
pharmaceutical technologies concerning polymeric micelle;
research, testing and analysis services for development of
products using polymeric micelle; testing, inspection or
research of pharmaceuticals, cosmetics and foodstuffs;
development of pharmaceutical products, cosmetic products
and foodstuffs; consultancy relating to development of
pharmaceutical products, cosmetic products and foodstuffs;
providing information related to development of
pharmaceutical products, cosmetic products and foodstuffs;
research and development in the pharmaceutical fields and
chemical fields; testing of products, product development,
product research; consultancy in the field of product
development; analysis and evaluation of product development.
12.
POLYMERIC MICELLE CARRIER COMPOSITION AND POLYMERIC MICELLE COMPOSITION
A polymeric micelle carrier composition comprising (i) a block copolymer having a hydrophilic polymer chain segment and a hydrophobic polymer chain segment, (ii) a charged surfactant and (iii) a fat or oil. The carrier composition can be used as a base material for a cosmetic composition or a pharmaceutical composition, and has excellent properties of carrying a non-lipophilic drug. One example of the non-lipophilic drug is a hair growth-promoting peptide.
A61K 47/34 - Composés macromoléculaires obtenus par des réactions autres que celles faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. polyesters, acides polyaminés, polysiloxanes, polyphosphazines, copolymères de polyalkylène glycol ou de poloxamères
A61K 47/42 - ProtéinesPolypeptidesLeurs produits de dégradationLeurs dérivés p. ex. albumine, gélatine ou zéine
A61K 47/44 - Huiles, graisses ou cires couvertes par plus d’un des groupes Huiles, graisses ou cires naturelles ou naturelles modifiées, p. ex. huile de ricin, huile de ricin polyéthoxylée, cire de lignite, lignite, gomme-laque, colophane, cire d’abeille ou lanoline
A61P 17/14 - Médicaments pour le traitement des troubles dermatologiques pour le traitement de la calvitie ou de l'alopécie
Disclosed is a polymer treatment agent comprising a block copolymer including a hydrophilic polymer chain segment and a hydrophobic polymer chain segment. This polymer treatment agent can be used not only to care for the hair on one's head, but also to care for body hair including eyelashes and eyebrows, and can increase physical strength of the hair even by using a very small amount and without using any silicone components. The strength-increasing effect is achieved particularly significantly in damaged hair.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Pharmaceutical preparations; pharmaceutical preparations and substances for the treatment of cancer; pharmaceutical preparations and substances for the prevention of cancer.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Pharmaceutical preparations; pharmaceutical preparations and substances for the prevention of cancer; pharmaceutical preparations and substances for the treatment of cancer.
Provided is a novel antibody against tissue factor. Also provided is a medicinal composition wherein the aforesaid antibody is used as a target binding factor. The antibody according to the present invention can exert an internalization ability into cells expressing tissue factor.
A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
This polymeric micelle pharmaceutical composition includes block copolymer units (α, β) which are provided with hydrophilic polymer chain segments and hydrophobic polymer chain segments. The block copolymer units (α, β) are radially arranged in a state in which the hydrophilic polymer chain segments are directed outwards and the hydrophobic polymer chain segments are directed inwards. The hydrophobic polymer chain segment of each block copolymer unit (α) is configured from repeating units provided with side chains, at least one of said side chains being provided with a hydrophilic group.
A61K 47/34 - Composés macromoléculaires obtenus par des réactions autres que celles faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. polyesters, acides polyaminés, polysiloxanes, polyphosphazines, copolymères de polyalkylène glycol ou de poloxamères
The present invention is capable of improving the retentivity of a nucleic acid such as siRNA in the blood by a carrier for delivery. A unit structure-type pharmaceutical composition of the present invention contains a nucleic acid and a block copolymer that has a cationic polyamino acid segment and a hydrophilic polymer chain segment. This unit structure-type pharmaceutical composition is electrically neutral since the positive charge of the cationic polyamino acid segment is offset by the negative charge of the nucleic acid; and the nucleic acid is covered with the hydrophilic polymer chain segment.
A61K 31/7088 - Composés ayant au moins trois nucléosides ou nucléotides
A61K 47/34 - Composés macromoléculaires obtenus par des réactions autres que celles faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. polyesters, acides polyaminés, polysiloxanes, polyphosphazines, copolymères de polyalkylène glycol ou de poloxamères
NATIONAL UNIVERSITY CORPORATION TOKYO MEDICAL AND DENTAL UNIVERSITY (Japon)
NANOCARRIER CO., LTD. (Japon)
Inventeur(s)
Kataoka, Kazunori
Ishii, Takehiko
Naito, Mitsuru
Matsumoto, Akira
Kato, Yasuki
Abrégé
The present invention provides a block copolymer which can act as a carrier that can achieve both the stability of a biotechnology-based drug in blood and the release of the biotechnology-based drug at an affected area. The block copolymer according to the present invention comprises a polyamino acid chain segment and a hydrophilic polymer chain segment, wherein the polyamino acid chain segment contains an amino acid residue having a cationic group in a side chain thereof and an amino acid residue having a phenylboronic acid group in a side chain thereof, wherein at least one hydrogen atom in a phenyl ring in the phenylboronic acid group is substituted so that the resultant block copolymer can have a pKa value close to the physiological pH value.
LABORATOIRE FRANCAIS DU FRACTIONNEMENT ET DES BIOTECHNOLOGIES (France)
Inventeur(s)
Arvis, Florence
Huille, Sylvain
Harada, Mitsunori
Abrégé
The invention relates to a pharmaceutical composition comprising factor VII encapsulated in micelles formed from block copolymer molecules containing (i) a hydrophilic polymer segment consisting of a polyalkylene glycol and (ii) a hydrophobic polymer segment consisting of a polyamino acid, with said polyamino acid comprising exclusively amino acid residues selected from the goup consisting of histidine, lysine, aspartic acid and glutamic acid residues, wherein a part of said amino acid residues is substituted with a hydrophobic group.
A61K 38/36 - Facteurs de coagulation sanguine ou de fibrinolyse
A61K 47/34 - Composés macromoléculaires obtenus par des réactions autres que celles faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. polyesters, acides polyaminés, polysiloxanes, polyphosphazines, copolymères de polyalkylène glycol ou de poloxamères
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A61P 7/04 - AntihémorragiquesProfacteurs de coagulationAgents hémostatiquesAgents antifibrinolytiques
The present invention provides a pharmaceutical composition. The pharmaceutical composition of the present invention is a pharmaceutical composition containing a block copolymer having a hydrophilic segment, a hydrophobic segment, and a boron compound linked to the side chain of the hydrophobic segment via a linker portion that includes a heterocyclic structure. The cyclic skeleton of the heterocycle has boron atoms derived from the boron compound, atoms (X) selected from oxygen and nitrogen atoms that bond with the boron atoms, and carbon atoms that bond with the atom (X), and the block copolymer further has organic groups that bond with the carbon atoms and contains aromatic groups or cyclic alkyl groups wherein the organic groups protect the boronic acid ester bonds and/or boron amide bonds attributed to the bonding of the boron atoms and the atoms (X).
The present invention provides a block copolymer which can be suitably used for a drug carrier capable of forming a stable complex with a nucleic acid and of releasing the nucleic acid intracellularly. The block copolymer is represented by formula (1) or (2). In the formulas, R1 and R2 are, independent of one another, a hydrogen atom or an optionally substituted C1-12 linear-chain or branched alkyl group, A is a hydrophilic polymer chain, L1 and L3 are linking groups, B is a cation-containing group, R3 is an arbitrary amino acid side chain, z is an integer between 5 and 500, x is an integer that is at least 40% of z, y is an integer and can be 0, z-x-y is an integer and can be 0, p is an integer between 1 and 10, and q is an integer between 1 and 10.
A61K 47/34 - Composés macromoléculaires obtenus par des réactions autres que celles faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. polyesters, acides polyaminés, polysiloxanes, polyphosphazines, copolymères de polyalkylène glycol ou de poloxamères
A61K 31/7088 - Composés ayant au moins trois nucléosides ou nucléotides
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
C07K 14/00 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés
C12N 15/113 - Acides nucléiques non codants modulant l'expression des gènes, p. ex. oligonucléotides anti-sens
23.
SHORT-CHAIN CATIONIC POLYAMINO ACID AND USE THEREOF
Provided is a cationic polyamino acid useful as a carrier which, together with a nucleic acid, can form a stable complex under physiologic conditions and which can appropriately release the nucleic acid in a cell. The cationic polyamino acid contains both a cationic amino acid residue that has a cationic group in the side chain and a hydrophobic amino acid residue that has a hydrophobic group in the side chain, and has an ability to associate with a nucleic acid. Further, the cationic polyamino acid contains 1 to 20 above-mentioned cationic amino acid residues, and is represented by general formula (1) [wherein each symbol is as defined in the description].
C07K 4/00 - Peptides ayant jusqu'à 20 amino-acides dans une séquence indéterminée ou partiellement déterminéeLeurs dérivés
A61K 31/7105 - Acides ribonucléiques naturels, c.-à-d. contenant uniquement des riboses liés à l'adénine, la guanine, la cytosine ou l'uracile et ayant des liaisons 3'-5' phosphodiester
A61K 31/713 - Acides nucléiques ou oligonucléotides à structure en double-hélice
A61K 47/42 - ProtéinesPolypeptidesLeurs produits de dégradationLeurs dérivés p. ex. albumine, gélatine ou zéine
A61K 47/48 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p.ex. supports, additifs inertes l'ingrédient non actif étant chimiquement lié à l'ingrédient actif, p.ex. conjugués polymère-médicament
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
C08G 69/48 - Polymères modifiés par post-traitement chimique
Disclosed is a particulate medicinal composition, which is suitable for a drug delivery system, having an improved drug-encapsulation stability. Specifically disclosed is a particulate medicinal composition (1) comprising block copolymer units (2), the block copolymer units being radially arranged with hydrophobic polymer chain segments (2b) facing inward and hydrophilic polymer chain segments (2a) facing outward, a drug (4) comprising a biopolymer, and a charged lipid (3) which is charged oppositely to the charge of the drug (4), wherein said charged lipid (3) is arranged in a state of being attracted toward the hydrophobic polymer chain segment (2b) side and the drug (3) is positioned inside of the hydrophobic polymer chain segments (2b). In this medicinal composition (1), drop off of the drug (4) outside particles can be remarkably prevented.
A61K 9/19 - Préparations médicinales caractérisées par un aspect particulier à l'état particulaire, p. ex. poudres lyophilisées
A61K 47/24 - Composés organiques, p. ex. hydrocarbures naturels ou synthétiques, polyoléfines, huile minérale, gelée de pétrole ou ozocérite contenant des atomes autres que des atomes de carbone, d'hydrogène, d'oxygène, d'halogènes, d'azote ou de soufre, p. ex. cyclométhicone ou phospholipides
A61K 47/34 - Composés macromoléculaires obtenus par des réactions autres que celles faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. polyesters, acides polyaminés, polysiloxanes, polyphosphazines, copolymères de polyalkylène glycol ou de poloxamères
Provided are: a polymeric micelle composition which can stably include a drug and can properly release the drug; and pharmaceutical compositions prepared using the polymeric micelle composition. The polymeric micelle composition has a structure wherein multiple block copolymers, which each have both a hydrophobic polymer chain segment (12) and a hydrophilic polymer chain segment (11), are radially arranged with the hydrophobic polymer chain segment (12) in the inside and with the hydrophilic polymer chain segment (11) in the outside. The composition contains, as the block copolymers, (A) a block copolymer (10) which has affinity for HDL (20) and (B) a block copolymer which has affinity for a lipoprotein other than HDL. When the block polymer (A) with HDL (20) is liberated from the polymeric micelle, a space is formed to accelerate the release of a drug (50) included in the polymeric micelle. The release rate of the drug (50) from the polymeric micelle can be adjusted by controlling the content ratio between the block polymers (A) and (B).
A61K 38/00 - Préparations médicinales contenant des peptides
A61K 47/34 - Composés macromoléculaires obtenus par des réactions autres que celles faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. polyesters, acides polyaminés, polysiloxanes, polyphosphazines, copolymères de polyalkylène glycol ou de poloxamères
A61K 47/42 - ProtéinesPolypeptidesLeurs produits de dégradationLeurs dérivés p. ex. albumine, gélatine ou zéine
26.
Liquid composition of cisplatin coordination compound
A liquid composition containing a polymer micelle and having a pH values of 3.0 to 7.0 is provided. The micelle is constituted of a coordination compound having a block copolymer of polyethylene glycol and polyglutamic acid and cisplatin that is coordinate-bonded to the block copolymer.
A61K 47/48 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p.ex. supports, additifs inertes l'ingrédient non actif étant chimiquement lié à l'ingrédient actif, p.ex. conjugués polymère-médicament
A61K 47/32 - Composés macromoléculaires obtenus par des réactions faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. carbomères
A01N 55/02 - Biocides, produits repoussant ou attirant les animaux nuisibles ou régulateurs de croissance des végétaux, contenant des composés organiques comportant des éléments autres que le carbone, l'hydrogène, les halogènes, l'oxygène, l'azote et le soufre contenant des atomes de métal
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
C08G 69/10 - Polyamides dérivés, soit des acides amino-carboxyliques, soit de polyamines et d'acides polycarboxyliques dérivés d'acides aminocarboxyliques d'acides alpha-aminocarboxyliques
C08G 69/40 - Polyamides contenant de l'oxygène sous forme de groupes éther
A particle composition comprising block copolymer units, which are arranged radially with hydrophobic polymer chain segments facing inward and hydrophilic polymer chain segments facing outward, and a charged lipid which is charged oppositely to the charge of a drug to be encapsulated, wherein said charged lipid is arranged in a state of being attracted to the hydrophobic polymer chain segment side. In this particle composition, a drug is held within the particles due to the electrostatic binding to the charged lipid, while the outer circumferential face of the particles is prevented from becoming electrically charged so as to attract a substance charged oppositely to the charged lipid.
A61K 31/7088 - Composés ayant au moins trois nucléosides ou nucléotides
A61K 31/715 - Polysaccharides, c.-à-d. ayant plus de cinq radicaux saccharide liés les uns aux autres par des liaisons glycosidiquesLeurs dérivés, p. ex. éthers, esters
A61K 38/00 - Préparations médicinales contenant des peptides
A61K 47/34 - Composés macromoléculaires obtenus par des réactions autres que celles faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. polyesters, acides polyaminés, polysiloxanes, polyphosphazines, copolymères de polyalkylène glycol ou de poloxamères
A61K 47/44 - Huiles, graisses ou cires couvertes par plus d’un des groupes Huiles, graisses ou cires naturelles ou naturelles modifiées, p. ex. huile de ricin, huile de ricin polyéthoxylée, cire de lignite, lignite, gomme-laque, colophane, cire d’abeille ou lanoline
A pharmaceutical composition or combination drug, which contains, as active ingredients, (a) a coordination compound composed of a block copolymer represented by the following formula I or formula II and cisplatin, and (b) gemcitabine hydrochloride.
3, m and n are as defined in the description.
A61K 47/48 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p.ex. supports, additifs inertes l'ingrédient non actif étant chimiquement lié à l'ingrédient actif, p.ex. conjugués polymère-médicament
The present invention provides an active targeting polymer micelle encapsulating a drug, preventing an inappropriate release of a drug which may damage a normal cell. A polymer micelle 100 includes a backbone polymer unit 10 that has a target binding site 11 and a backbone polymer unit 20 that has a drug 14 and is free from the target binding site 11, such polymer units 10 and 20 being disposed in a radial arrangement in a state where the target binding site 11 is directed outward and the drug 14 is directed inward, in which: i) when the micelle is bound to a target 40 while maintaining the radial arrangement, the micelle is taken up into a cell 50 supplying the target 40 through endocytosis, and the drug 14 is released into the cell 50 by collapse of the radial arrangement in the cell 50; and ii) when the radial arrangement collapses in blood 60 before the micelle is bound to a target 40, the unit 20 is excreted through metabolism, to thereby prevent a normal cell from being damaged by the drug 14.
A61K 47/48 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p.ex. supports, additifs inertes l'ingrédient non actif étant chimiquement lié à l'ingrédient actif, p.ex. conjugués polymère-médicament
Provided is an active targeting type polymeric micelle carrying a drug enclosed therein wherein inappropriate drug release possibly impairing normal cells can be prevented. A polymeric micelle (100) which comprises a skeleton polymer unit (10) having a target-binding site (11) and a skeleton polymer unit (20) carrying a drug (14) but not having the target-binding site (11), wherein these units (10 and 20) are arranged radially with the target-binding site (11) outward and the drug (14) inside. In the case (i) wherein the polymeric micelle binds to a target (40) while sustaining the radial arrangement, the polymeric micelle is incorporated by endocytosis into a cell (50) providing the target (40) and then the radial arrangement is broken in the cell (50) so that the drug (14) is released within the cell (50). In the case (ii) wherein the radial arrangement is broken in the blood (60) before the binding to the target (40), the units (20) are discharged from the body by the metabolism so that the impairment of normal cells by the drug (14) can be prevented.
A61K 47/48 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p.ex. supports, additifs inertes l'ingrédient non actif étant chimiquement lié à l'ingrédient actif, p.ex. conjugués polymère-médicament
Disclosed is a liquid composition. The liquid composition is characterized by comprising a polymer micelle, wherein the polymer micelle comprises a coordinate compound comprising a block copolymer of polyethylene glycol and polyglutamaic acid and cisplatin attached to the block copolymer through a coordinate bond. The liquid composition is also characterized by having a pH value of 3.0 to 7.0.
A61K 47/10 - AlcoolsPhénolsLeurs sels, p. ex. glycérolPolyéthylène glycols [PEG]PoloxamèresAlkyléthers de PEG/POE
A61K 47/34 - Composés macromoléculaires obtenus par des réactions autres que celles faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. polyesters, acides polyaminés, polysiloxanes, polyphosphazines, copolymères de polyalkylène glycol ou de poloxamères
A61K 47/48 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p.ex. supports, additifs inertes l'ingrédient non actif étant chimiquement lié à l'ingrédient actif, p.ex. conjugués polymère-médicament
Disclosed is a camptothecin polymer derivative prepared by linking a carboxyl group of a block copolymer comprising polyethylene glycols and polyaspartic acid, with a camptothecin hydroxyl group, through ester bonds.
C08G 69/48 - Polymères modifiés par post-traitement chimique
A61K 31/4745 - QuinoléinesIsoquinoléines condensées en ortho ou en péri avec des systèmes hétérocycliques condensées avec des systèmes cycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. phénanthrolines
A61K 47/48 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p.ex. supports, additifs inertes l'ingrédient non actif étant chimiquement lié à l'ingrédient actif, p.ex. conjugués polymère-médicament
Provided is a method for producing a Docetaxel polymer derivative by ester bonding any one or more of the hydroxyl groups of Docetaxel with the aspartic acid side chain carboxyl groups of a block copolymer including polyethylene glycol and polyaspartic acid. The rate of release of the Docetaxel from the Docetaxel polymer derivative so obtained is regulated by adjusting the proportion of bound Docetaxel on the block copolymer and/or the number of bonds.
C08G 69/40 - Polyamides contenant de l'oxygène sous forme de groupes éther
A61K 31/337 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p. ex. fungichromine ayant des cycles à quatre chaînons, p. ex. taxol
A61K 47/34 - Composés macromoléculaires obtenus par des réactions autres que celles faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. polyesters, acides polyaminés, polysiloxanes, polyphosphazines, copolymères de polyalkylène glycol ou de poloxamères
A61K 47/48 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p.ex. supports, additifs inertes l'ingrédient non actif étant chimiquement lié à l'ingrédient actif, p.ex. conjugués polymère-médicament
Disclosed is a pharmaceutical composition or combined agent, which contains, as active ingredients, (a) a coordination compound composed of a block copolymer represented by formula (I) or (II) and cisplatin, and (b) gemcitabine hydrochloride. (I) (II) [In the formulae (I) and (II), R1, A, R2, R3, m and n are as defined in the description.]
A61K 31/7068 - Composés ayant des radicaux saccharide et des hétérocycles ayant l'azote comme hétéro-atome d'un cycle, p. ex. nucléosides, nucléotides contenant des cycles à six chaînons avec l'azote comme hétéro-atome d'un cycle contenant des pyrimidines condensées ou non-condensées ayant des groupes oxo liés directement au cycle pyrimidine, p. ex. cytidine, acide cytidylique
A61K 47/48 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p.ex. supports, additifs inertes l'ingrédient non actif étant chimiquement lié à l'ingrédient actif, p.ex. conjugués polymère-médicament
Disclosed is a block copolymer for a drug complex, which comprises a water-soluble polymeric segment comprising a polyethylene glycol and a polyamino acid segment having a hydrazide group and a hydrophobic group in a side chain.
C08G 81/00 - Composés macromoléculaires obtenus par l'interréaction de polymères en l'absence de monomères, p. ex. polymères séquencés
A61K 31/706 - Composés ayant des radicaux saccharide et des hétérocycles ayant l'azote comme hétéro-atome d'un cycle, p. ex. nucléosides, nucléotides contenant des cycles à six chaînons avec l'azote comme hétéro-atome d'un cycle
A61K 47/48 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p.ex. supports, additifs inertes l'ingrédient non actif étant chimiquement lié à l'ingrédient actif, p.ex. conjugués polymère-médicament
It is intended to provide a transdermal composition comprising a polymer micelle encapsulating a transdermally absorbed active ingredient with a block copolymer having a hydrophobic region and a hydrophilic region as a whole; a transdermal pharmaceutical composition comprising a polymer micelle containing a transdermally absorbed pharmaceutically active ingredient; and a transdermal cosmetic composition comprising a polymer micelle containing a transdermally absorbed cosmetically active ingredient.
A61K 31/122 - Cétones ayant l'atome d'oxygène lié directement à un cycle, p. ex. quinones, vitamine K1, anthraline
A61K 31/194 - Acides carboxyliques, p. ex. acide valproïque ayant plusieurs groupes carboxyle, p. ex. acides succinique, maléique ou phtalique
A61K 31/375 - Acide ascorbique, c.-à-d. vitamine CSes sels
A61K 31/522 - Purines, p. ex. adénine ayant des groupes oxo liés directement à l'hétérocycle, p. ex. hypoxanthine, guanine, acyclovir
A61K 31/56 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrèneLeurs dérivés, p. ex. stéroïdes
A61K 31/59 - Composés contenant le système cyclique du 9,10-séco-cyclopenta[a]hydrophénanthrène
A61K 45/00 - Préparations médicinales contenant des ingrédients actifs non prévus dans les groupes
A61K 47/34 - Composés macromoléculaires obtenus par des réactions autres que celles faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. polyesters, acides polyaminés, polysiloxanes, polyphosphazines, copolymères de polyalkylène glycol ou de poloxamères
A61P 25/04 - Analgésiques centraux, p. ex. opioïdes
A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
Disclosed is a polymer micelle composition which comprises a physiologically active polypeptide or protein enclosed therein, and which is derived from a block copolymer having a hydrophilic segment and a hydrophobic segment.
A61K 39/395 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire
A61K 47/34 - Composés macromoléculaires obtenus par des réactions autres que celles faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. polyesters, acides polyaminés, polysiloxanes, polyphosphazines, copolymères de polyalkylène glycol ou de poloxamères
38.
PROCESS FOR PRODUCING POLYMER MICELLE ENCLOSING HYDROPHOBIC DRUG
A method of causing a polymer micelle to enclose a hydrophobic drug. The method comprises the steps of (1-a) dissolving or dispersing a hydrophobic drug in a lower alcohol; (1-b) providing an aqueous medium containing a polymer micelle consisting of a block copolymer with hydrophilic region and hydrophobic region; and (1-c) mixing the lower alcohol solution or dispersion having the hydrophobic drug dissolved or dispersed therein with the aqueous medium containing the polymer micelle to thereby cause the polymer micelle to enclose the hydrophobic drug. The solubility in water of the hydrophobic drug is lower than the solubility in the lower alcohol.
A61K 45/00 - Préparations médicinales contenant des ingrédients actifs non prévus dans les groupes
A61K 47/34 - Composés macromoléculaires obtenus par des réactions autres que celles faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. polyesters, acides polyaminés, polysiloxanes, polyphosphazines, copolymères de polyalkylène glycol ou de poloxamères
A61K 47/36 - PolysaccharidesLeurs dérivés, p. ex. gommes, amidon, alginate, dextrine, acide hyaluronique, chitosane, inuline, agar-agar ou pectine
A61K 47/42 - ProtéinesPolypeptidesLeurs produits de dégradationLeurs dérivés p. ex. albumine, gélatine ou zéine
39.
METHOD OF PRODUCING POLYMER MICELLE HAVING LOW MOLECULAR CHEMICAL ENCAPSULATED THEREIN
A method of encapsulating a low molecular chemical in a polymer micelle which comprises the following steps: (a) dissolving or dispersing the above-described chemical, which has been electrically charged, in an aqueous medium; (b) preparing an aqueous medium containing the polymer micelle as described above which comprises an area having a hydrophobic side chain and a side chain charged oppositely to the low molecular chemical distributed at random and being hydrophobic as a whole and a hydrophilic area; (c) mixing the aqueous medium having the low molecular chemical dissolved or dispersed therein with the aqueous medium containing the polymer micelle; and (d) adjusting the aqueous medium mixture thus obtained to a pH value at which the encapsulation of the low molecular chemical is stabilized.
A61K 47/34 - Composés macromoléculaires obtenus par des réactions autres que celles faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. polyesters, acides polyaminés, polysiloxanes, polyphosphazines, copolymères de polyalkylène glycol ou de poloxamères
A61K 47/42 - ProtéinesPolypeptidesLeurs produits de dégradationLeurs dérivés p. ex. albumine, gélatine ou zéine
A61K 31/4745 - QuinoléinesIsoquinoléines condensées en ortho ou en péri avec des systèmes hétérocycliques condensées avec des systèmes cycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. phénanthrolines
A61K 31/704 - Composés ayant des radicaux saccharide liés à des composés non-saccharide par des liaisons glycosidiques liés à un composé carbocyclique, p. ex. phloridzine liés à un système carbocyclique condensé, p. ex. sennosides, thiocolchicosides, escine, daunorubicine, digitoxine
A stabilizer for hydrophobic compounds, particularly hinokitiol, which consists of a block copolymer comprising a hydrophilic segment and a hydrophobic segment as the essential components.
A61P 43/00 - Médicaments pour des utilisations spécifiques, non prévus dans les groupes
A61K 47/34 - Composés macromoléculaires obtenus par des réactions autres que celles faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. polyesters, acides polyaminés, polysiloxanes, polyphosphazines, copolymères de polyalkylène glycol ou de poloxamères
41.
PROCESS FOR PRODUCING PHARMACEUTICAL COMPOSITION CONTAINING DRUG-ENCAPSULATING POLYMER MICELLE USING FLUORINE-CONTAINING ORGANIC SOLVENT
It is intended to provide a production process which is a process for producing a pharmaceutical composition containing a polymer micelle encapsulating a hydrophobic drug, characterized by comprising the step of dissolving a block copolymer composed of a hydrophilic segment and a hydrophobic segment and the hydrophobic drug in a volatile fluorine-containing organic solvent.
A61K 31/337 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p. ex. fungichromine ayant des cycles à quatre chaînons, p. ex. taxol
A61K 31/407 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à cinq chaînons avec un azote comme seul hétéro-atome d'un cycle, p. ex. sulpiride, succinimide, tolmétine, buflomédil condensés avec des systèmes hétérocycliques, p. ex. kétorolac, physostigmine
A61K 31/4709 - Quinoléines non condensées contenant d'autres hétérocycles
A61K 31/4745 - QuinoléinesIsoquinoléines condensées en ortho ou en péri avec des systèmes hétérocycliques condensées avec des systèmes cycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. phénanthrolines
A61K 31/475 - QuinoléinesIsoquinoléines ayant un cycle indole, p. ex. yohimbine, réserpine, strychnine, vinblastine
A61K 31/519 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime condensées en ortho ou en péri avec des hétérocycles
A61K 31/5575 - Eicosanoïdes, p. ex. leucotriènes ayant un cycle cyclopentane, p. ex. prostaglandine E2, prostaglandine F2-alpha
A61K 31/704 - Composés ayant des radicaux saccharide liés à des composés non-saccharide par des liaisons glycosidiques liés à un composé carbocyclique, p. ex. phloridzine liés à un système carbocyclique condensé, p. ex. sennosides, thiocolchicosides, escine, daunorubicine, digitoxine
A61K 31/7048 - Composés ayant des radicaux saccharide et des hétérocycles ayant l'oxygène comme hétéro-atome d'un cycle, p. ex. leucoglucosane, hespéridine, érythromycine, nystatine
A61K 47/30 - Composés macromoléculaires organiques ou inorganiques, p. ex. polyphosphates inorganiques
A61K 47/34 - Composés macromoléculaires obtenus par des réactions autres que celles faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. polyesters, acides polyaminés, polysiloxanes, polyphosphazines, copolymères de polyalkylène glycol ou de poloxamères
A61K 47/42 - ProtéinesPolypeptidesLeurs produits de dégradationLeurs dérivés p. ex. albumine, gélatine ou zéine
